Exploring dosing frequency and administration routes in the treatment of anaemia in CKD patients
Erythropoiesis-stimulating agents have dramatically changed the management of renal anaemia since their introduction almost 20 years ago. However, optimal dosing route and frequency are still a matter of debate. Intravenous application of recombinant human erythropoietin should be limited to haemodi...
Saved in:
Published in | Nephrology, dialysis, transplantation Vol. 20; no. suppl-8; pp. viii13 - viii17 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
England
Oxford University Press
01.09.2005
Oxford Publishing Limited (England) |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Erythropoiesis-stimulating agents have dramatically changed the management of renal anaemia since their introduction almost 20 years ago. However, optimal dosing route and frequency are still a matter of debate. Intravenous application of recombinant human erythropoietin should be limited to haemodialysis patients and must be given three times weekly, as any reduction to this dosing frequency leads to a major increase in dose requirements. Administering recombinant human erythropoietin-β once weekly via the subcutaneous route is effective. If conversion from the subcutaneous to the intravenous route is required, dose requirements for recombinant human erythropoietin therapy remain a subject of discussion. |
---|---|
Bibliography: | istex:C880DE5994AFD29EEEAC43ADB8E96476245C5351 local:gfh1111 Correspondence and offprint requests to: Jose Portolés MD, PhD, Head of Nephrology Unit, Fundación Hospital Alcorcón, Avda villaviciosa s.n. Alcorcón, 28922 Madrid, Spain. Email: jmportoles@fhalcorcon.es ark:/67375/HXZ-PDDNXGVQ-3 ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 |
ISSN: | 0931-0509 1460-2385 |
DOI: | 10.1093/ndt/gfh1111 |